Colinz Laboratories Limited (BOM:531210)

India flag India · Delayed Price · Currency is INR
46.00
+1.00 (2.22%)
At close: Apr 28, 2026
-19.01%
Market Cap 120.51M
Revenue (ttm) 58.40M
Net Income (ttm) 4.94M
Shares Out 2.52M
EPS (ttm) 1.96
PE Ratio 24.41
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 75
Average Volume 576
Open 46.00
Previous Close 45.00
Day's Range 46.00 - 46.00
52-Week Range 36.11 - 87.91
Beta -0.02
RSI 54.10
Earnings Date Apr 29, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,... [Read more]

Industry Pharmaceutical Preparations
Founded 1986
Employees 65
Stock Exchange Bombay Stock Exchange
Ticker Symbol 531210
Full Company Profile

Financial Performance

In fiscal year 2025, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.

Financial Statements

News

There is no news available yet.